AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00941642
Drug: placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 50% of study subjects will be randomized to the placebo arm of this study. Placebo arm subjects will receive 4g of placebo gel caps daily for a minimum of 48 weeks duration.
Trial: NCT04128800
Drug: Apatinib S-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apatinib 250 mg PO qd; S-1 40 mg PO in the morning and 60 mg PO in the evening; 14 days in combination, 21 days in a cycle.
Trial: NCT00365274
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV 750 mg/m\^2 day 1
Trial: NCT00365274
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given 50 mg/m\^2 IV day 1
Trial: NCT01089309
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone orally, at a dose of 50 mg/day for 12 months
Trial: NCT00192023
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02173145
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin is a macrolide antibiotic. 500mg Azithromycin will be given p.o. 3 times a week for 3 months. Azithromycin will be compared to placebo.
Trial: NCT02173145
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given 3 times a wek over a period of 3 months.
Trial: NCT01114672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo once weekly
Trial: NCT00934414
Drug: Technosphere Insulin Inhalation Powder
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30U
Trial: NCT01672593
Drug: Anti-Bacterial Agents
RxNorm normalized name: INVESTIGATIONAL ANTI-BACTERIAL DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial therapy was given to patients with signs of systemic sepsis or local inflammation with pain.
Trial: NCT00429897
Drug: Bendroflumethiazide 2.5mg - 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00429897
Drug: Amiloride 20-40mg
RxNorm normalized name: amiloride 20 MG / furosemide 40 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00429897
Drug: Spironolactone 50-100mg
RxNorm normalized name: spironolactone 100 MG
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00429897
Drug: Frusemide 20-40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00429897
Drug: Bendroflumethiazide 1.25-2.5mg/ Amiloride 10-20mg combined
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04049903
Drug: MP0310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors
Trial: NCT03748836
Drug: ALPN-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple doses of ALPN-101 delivered via intravenous or subcutaneous injection. Ascending dose levels will be evaluated.
Trial: NCT03748836
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple doses of placebo delivered via intravenous or subcutaneous injection, matched to ALPN-101 cohorts.
Trial: NCT01133574
Drug: SLV354 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg
Trial: NCT01133574
Drug: SLV354 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg
Trial: NCT01133574
Drug: SLV354 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg
Trial: NCT01133574
Drug: SLV354 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg
Trial: NCT01133574
Drug: SLV354 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg
Trial: NCT01133574
Drug: SLV354 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg
Trial: NCT01133574
Drug: SLV354 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high dose group 1
Trial: NCT01133574
Drug: SLV354 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose group 2
Trial: NCT01133574
Drug: SLV354 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high dose group 2
Trial: NCT02205099
Drug: SKL15508
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02205099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01133574
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03900377
Drug: SyB L-0501RI
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The specified dose of SyB L-0501RI and rituximab will be administered by intravenous rapid infusion over 10 minutes on specified days.
Trial: NCT02891044
Drug: BAY987517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z44-040)
Trial: NCT03885804
Drug: Quadratus lamborum dexmedetomidine perineural group(
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive quadratus lamborum block on the same surgical side then1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.
Trial: NCT02792647
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00104637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg po tid
Trial: NCT01313624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match AZLI administered via nebulizer three times daily
Trial: NCT01742091
Drug: LY2541546 - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT01742091
Drug: Placebo - SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01742091
Drug: Placebo - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT01072968
Drug: BF2.649
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule per day in the morning before the breakfast
Trial: NCT01072968
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule per day in the morning before the breakfast
Trial: NCT02281968
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standing regimen of naproxen in experimental group to reduce need for narcotic to control pain
Trial: NCT02281968
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01598207
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg BID, orally for 1 month
Trial: NCT02580240
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).
Trial: NCT01444872
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT02277808
Drug: 500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%)
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00176410
Drug: fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg fluvastatin daily
Trial: NCT03049345
Drug: Radioactive Tracers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see above
Trial: NCT02649361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo p.o. qd
Trial: NCT00616330
Drug: clindamycin phosphate/butoconazole nitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semi solid, single dose
Trial: NCT00616330
Drug: clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: semi solid, single dose
Trial: NCT00966030
Drug: MK0974 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0974 280 mg tablet in one of two treatment periods
Trial: NCT00966030
Drug: Comparator: MK0974 liquid filled capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0974 300 mg liquid filled capsule in one of two treatment periods
Trial: NCT00027976
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00027976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03043482
Drug: Single VS-105/placebo to healthy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 1, single ascending doses of VS-105 or placebo will be administered to approximately 5 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo.
Trial: NCT03043482
Drug: Multiple VS-105/placebo to healthy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 2, multiple ascending doses of VS 105 or placebo will be administered each morning over 7 consecutive days to approximately 3 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo..
Trial: NCT03043482
Drug: Multiple VS-105/placebo to HD subjects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 3, multiple ascending doses of VS 105 will be administered over 14 consecutive days to approximately 3 cohorts that will each include 4 hemodialysis subjects with 3 receiving active drug and 1 receiving placebo.
Trial: NCT02893098
Drug: Humia inj.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of 3mL Humia inj.~Dummy: Single injection 2ml Normal Saline inj. given weekly for 2 weeks
Trial: NCT02893098
Drug: High hyal Plus inj.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Injection of 2mL High hyal Plus inj. given weekly for 3 weeks
Trial: NCT04054414
Drug: PMZ-1620 along with standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Trial: NCT00673127
Drug: Ketoconazole, Hydrocortisone and Dutasteride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Pills should be taken with food or milk.~Dutasteride: 0.5mg orally once a day on an empty stomach or after eating a meal
Trial: NCT00119262
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02312011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00119262
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00119262
Drug: aromatase inhibition therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive aromatase inhibition therapy
Trial: NCT01338376
Drug: Scilin®M30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be treated with Scilin®M30 twice daily
Trial: NCT02480803
Drug: Continuous intrajejunal infusion of levodopa-carbidopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous delivery of levodopa-carbidopa intestinal gel through an intrajejunal percutaneous tube (Duodopa, CLI, CILI)
Trial: NCT00001626
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide
Trial: NCT04567810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
Trial: NCT01458847
Drug: cis-UCA solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort I: 2% cis-UCA solution (50 ml); min 3, max 12 patients
Trial: NCT01458847
Drug: cis-UCA solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort II: 4% cis-UCA solution (50 ml); min 0, max 12 patients
Trial: NCT01458847
Drug: cis-UCA solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort III: 6% cis-UCA solution (50 ml); min 0, max 12 patients
Trial: NCT02164097
Drug: ODSH
RxNorm normalized name: Octasulfated Disaccharide Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03401047
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive graded doses of transdermal estradiol patches for up to 7 days. Blood estradiol tests will be performed daily, and the number of estradiol patches used will be adjusted to maintain serum estradiol levels of 250-400 pg/ml. Estradiol is a natural hormone.
Trial: NCT02744339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sham-titrated TID
Trial: NCT00985270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03051893
Drug: Chronocort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified formulation of hydrocortisone
Trial: NCT02781311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, orally, BID for 24 weeks.
Trial: NCT01813305
Drug: CSTC1 Matched vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05006222
Drug: Enzyme Replacement Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy is one such treatment and used for the management of some subtypes of MPS disease. Enzyme replacement therapy (ERT) is based on the concept of replacing the missing enzyme in the circulation to prevent the build-up of glycosaminoglycan (GAG) in the tissues
Trial: NCT01999777
Drug: USL261
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01999777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01098526
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1349572 is an experimental drug under development for the treatment of HIV. It is in the class of integrase inhibitors.
Trial: NCT04639986
Drug: Capecitabine Oral Product
RxNorm normalized name: capecitabine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine is administered orally (PO) following recommended doses and regimens as per approved package inserts.
Trial: NCT00814645
Drug: Placebo and AIR001 Inhalation Solution (Expansion arm)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
Trial: NCT00338260
Drug: MK0954, /Duration of Treatment : 5 Years
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI placebo daily for 15 months
Trial: NCT01155791
Drug: Biosyn
RxNorm normalized name: biosynthetic glove
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dosage varies
Trial: NCT04542408
Drug: Anticoagulation Agents (Edoxaban and/or high dose LMWH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital (ICU \& normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC until
Trial: NCT04542408
Drug: Low dose Low molecular weight heparin or Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital (ICU \& normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral pla-cebo according to the dosing rules for Edoxaban
Trial: NCT02729935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An equal volume of saline
Trial: NCT02039661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03588598
Drug: SHC014748M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a selective PI3Kδ inhibitor
Trial: NCT00914290
Drug: IPX056
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPX056 ER capsule containing 10 mg baclofen
Trial: NCT01028079
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 1000 mg (solid dose caplet) to be given three times daily as for 2 consecutive days (48 hours), followed by Aspirin 1000 mg (solid dose caplet) to be taken as per need, but not more than three times daily for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 3000 mg Aspirin.
Trial: NCT00428025
Drug: diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg diclofenac rectal suppository
Trial: NCT00428025
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: similar shape and size suppository
Trial: NCT00801411
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00801411
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01028079
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400 mg caplet to be given three times a day as for 2 consecutive days (48 hours), followed by ibuprofen 400 mg caplet to be given as per need, but not more than three times a day for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 1200 mg ibuprofen.
Trial: NCT01028079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two placebos: Placebo Aspirin and Placebo Ibuprofen) to be given three times a day for a maximum of 5 consecutive days in the same regimen as for Experimental Drug and Active Comparator.
Trial: NCT02146222
Drug: VEGFR/PDGFR dual kinase inhibitor X-82
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04292314
Drug: Nigella Sativa Oil
RxNorm normalized name: Nigella sativa seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months
Trial: NCT01227928
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 800 mg daily for 24 months
Trial: NCT01084993
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70 U/kg
Trial: NCT01267981
Drug: Standard diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the lunch the day before the exploration, drink only clear liquids and stop solid food.~From 10 pm, stay fasting, don't drink except the usual drugs taken with mouthful of water until the exploration by video-capsule endoscopy.
Trial: NCT03192969
Drug: Glucocorticoid Treatment
RxNorm normalized name: Glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)
Trial: NCT01190722
Drug: etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg once daily for the 1st 6 postoperative days
Trial: NCT01190722
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg oral 3 times daily the 1st 6 postoperative days
Trial: NCT00338988
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1500 mg/m\^2 PO twice daily x 14 days.
Trial: NCT03616795
Drug: LY3154207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03616795
Drug: [14C]-LY3154207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03293069
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the placebo twice daily morning and evening.
Trial: NCT02680119
Drug: Nexium 40 mg DR Capsules of AstraZeneca LP, USA.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, crossover
Trial: NCT00405704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cherry flavored liquid suspension matched to active comparator.
Trial: NCT04134884
Drug: ASTX727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASTX727 will be taken on days 1 and 3, days 1,3,5 or days 1 through 5 of the 28 day cycle at doses of 10 mg:100 mg or 15 mg:100 mg depending on cohort assignment
Trial: NCT04529811
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo